

# Enantioselective formal synthesis of antitumor agent (+)-ottelione A

Mi Young Lee<sup>a</sup>, Kyung Hwa Kim<sup>a</sup>, Shuai Jiang<sup>a</sup>, Yoo Hyun Jung<sup>a</sup>, Jae Yi Sim<sup>a</sup>,  
Geum-Sook Hwang<sup>b,\*</sup>, Do Hyun Ryu<sup>a,\*</sup>

<sup>a</sup> Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Republic of Korea

<sup>b</sup> Korea Basic Science Institute, 5St, Anam-Dong, Seongbuk-Gu, Seoul 136-701, Republic of Korea

Received 17 December 2007; revised 14 January 2008; accepted 21 January 2008


Available online 30 January 2008

## Abstract

The enantioselective formal synthesis of a natural antitumor product, (+)-ottelione A, was achieved through a catalytic enantioselective Diels–Alder strategy. These endeavors have led to the synthesis of a variety of synthetic analogues of this biologically potent natural product.

© 2008 Elsevier Ltd. All rights reserved.

Ottelione A, **1** was isolated from the widely occurring fresh water plant, *Ottelia alismoides*, by the Hoye group.<sup>1</sup> Ottelione A showed quite remarkable biological activity, such as antitubercular<sup>2</sup> and antitumor activities.<sup>1</sup> Screening against a panel of 60 human cancer cell lines at the National Cancer Institute in the United States revealed the cytotoxicity of compound **1** at the nM–pM levels.<sup>1</sup> Biological studies by a research group at Aventis reported that compound **1** is an efficient inhibitor of tubulin polymerization ( $IC_{50} = 1.2 \mu\text{M}$ ) and can disassemble preformed microtubules to represent a new class of inhibitor of microtubule assembly with potential therapeutic value.<sup>3</sup> However, the rarity of this natural product has prevented further extensive biological studies. Since the first synthesis of racemic compound **1** was reported,<sup>4a</sup> the enantioselective total syntheses of compound **1** was reported by Mehta<sup>4b</sup>, Katoh<sup>4c,d</sup> and Clive<sup>4e</sup> groups, and the absolute configuration of compound **1** was assigned by their syntheses. This Letter reports the efficient asymmetric synthesis of compound **2**, which Mehta and co-workers had previously converted to the natural product **1** (Scheme 1).



Scheme 1. Retrosynthetic analysis of (+)-ottelione A **1**.


As part of an ongoing investigation into catalytic enantioselective Diels–Alder reactions,<sup>5</sup> we considered that the selective oxidative cleavage of the Diels–Alder adduct **3** could provide the intermediate lactone **2**. In addition, it was envisaged that the enantioselective Diels–Alder reaction between 2-iodo-1,4-quinone monoketal **4** and cyclopentadiene would provide chiral *endo*-Diels–Alder adduct **3**, which has the correct *cis*-bicyclic core structure.

The cationic chiral oxazaborolidinium catalysts **5** generated from the corresponding oxazaborolidines via protonation by trifluoromethanesulfonic acid are excellent catalysts for an enantioselective Diels–Alder reaction with a variety of dienes and dienophiles, for example


\* Corresponding authors. Tel.: +82 2 920 0737; fax: +82 2 920 0779 (G.-S.H.); tel.: +82 31 290 5931; fax: +82 31 290 5976 (D.H.R.).

E-mail addresses: [gshwang@kbsi.re.kr](mailto:gshwang@kbsi.re.kr) (G.-S. Hwang), [dhryu@skku.edu](mailto:dhryu@skku.edu) (D. H. Ryu).


$\alpha,\beta$ -enones, esters and quinone monoketals.<sup>5</sup> Recently, it was found that the Diels–Alder reaction of furans with catalyst **5** provides 7-oxabicyclo [2.2.1] hept-5-enes with high *endo*-selectivity and excellent enantioselectivity.<sup>6</sup>




Initially, the enantioselective Diels–Alder reactions of cyclopentadiene and 2-iodo-1,4-quinone monoketal **4**, which is easily prepared from 2-iodophenol,<sup>7</sup> were attempted. The reaction was carried out at  $-78\text{ }^\circ\text{C}$  by stirring 2-iodo-1,4-quinone monoketal **4** and cyclopentadiene in the presence of **ent-5** (20 mol %) in  $\text{CH}_2\text{Cl}_2$  under nitrogen. The reaction was complete after 2 h. Only the *endo*-cycloadduct **3** was generated in 95% yield with excellent 95% ee. Enantioselectivities were determined by HPLC analysis using chiralcel OJ-H column with hexane-*i*PrOH (9:1) for elution.



The next stage is the preparation of the key intermediate **11** from the chiral Diels–Alder *endo*-adduct **3**. After the Luche reduction of adduct **3** using sodium borohydride in the presence of cerium chloride,<sup>8</sup> alcohol **6** was subjected to ozonolysis to give the 5-*exo* cyclized product **8** through the intermediate **7**. However, the lactol **8** was a mixture of diastereomers. Epimerization with DBU<sup>4c</sup> provided aldehyde **9** with all requisite stereocenters in 78% yield in three steps. A Wittig reaction with a methylphosphonium salt using NaHMDS<sup>9</sup> introduced the vinyl group in 97% yield. The structure of compound **10** was determined unambiguously from the NOESY and COSY spectra. The removal of iodine was performed using tributyltin hydride to afford compound **11** in 95% yield (Scheme 2).



Scheme 2. Reagents and conditions: (a)  $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ , MeOH,  $\text{NaBH}_4$ ,  $-78\text{ }^\circ\text{C}$ ; (b) (i)  $\text{O}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-78\text{ }^\circ\text{C}$ , (ii)  $\text{Me}_2\text{S}$ , rt; (c) DBU, benzene,  $65\text{ }^\circ\text{C}$ , 78% (three step); (d)  $\text{Ph}_3\text{PCH}_3^+\text{Br}$ , NaHMDS, THF,  $0\text{ }^\circ\text{C}$ , 97%; (e)  $n\text{-Bu}_3\text{SnH}$ , benzene,  $80\text{ }^\circ\text{C}$ , 95%.



Scheme 3. Reagents and conditions: (a) 1N  $\text{H}_2\text{SO}_4$ , acetone, THF,  $0\text{ }^\circ\text{C} \rightarrow \text{rt}$ , 93%; (b) PCC, Celite,  $\text{CH}_2\text{Cl}_2$ , rt, 95%; (c)  $(\text{IPr})\text{Cu}(\text{OAc})_2$ , PMHS, toluene,  $t\text{-BuOH}$ , rt, 87%; (d)  $\text{Ph}_3\text{PCH}_3^+$ , NaHMDS, benzene,  $80\text{ }^\circ\text{C}$ , 65%.




Fig. 1. The transition-state assembly of the Diels–Alder reaction of cyclopentadiene and **4** in the presence of *ent-5*.

Deprotection of ketal, followed by pyridinium chlorochromate oxidation of lactol **12**, gave lactone **13** in two steps in 88% yield. Finally, the reduction of the conjugated ketone<sup>10</sup> and a Wittig reaction of ketone **14** were carried out efficiently to release the known intermediate **2**. The spectral data and optical rotation of the synthetic compound **2** were in well accord with that of the reported one<sup>4a,b</sup> (Scheme 3).

As we predicted, the mechanistic model of cationic oxazabororidinium catalyst *ent-5* was supported (Fig. 1).<sup>5</sup> For  $\alpha,\beta$ -unsaturated carbonyl compounds having an  $\alpha$ -C–H substituent (e.g., esters, quinones, ketones)  $\alpha$ -C–H $\cdots$ O hydrogen bonding leads to a preferred pathway.

In summary, the bicyclic core intermediate **2** for the synthesis of (+)-ottelione A was synthesized using a catalytic enantioselective Diels–Alder strategy. A variety of chiral derivatives were obtained using this method and their anticancer activities will be reported elsewhere.

## Acknowledgements

This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD)(KRF-2005-005-J11901 and KRF-2005-070-C00073) and by KBSI Grant (N26043) to G.-S.H.

## References and notes

1. Ayyad, S.-E. N.; Judd, A. S.; Shier, W. T.; Hoye, T. R. *J. Org. Chem.* **1998**, *63*, 8102.
2. Li, H.; Qu, X.; Shi, Y.; Guo, L.; Yuan, Z. *Zhongguo Zhongyao Zazhi (Chin. J. Chin. Mater. Med.)* **1995**, *20*, 115, 128.
3. Combeau, C.; Provost, J.; Lancelin, F.; Tournoux, Y.; Prod'homme, F.; Herman, F.; Lavelle, F.; Leboul, J.; Vuilhorgne, M. *Mol. Pharmacol.* **2000**, *57*, 553.
4. (a) Mehta, G.; Islam, K. *Angew. Chem., Int. Ed.* **2002**, *41*, 2496; (b) Mehta, G.; Islam, K. *Tetrahedron Lett.* **2003**, *44*, 6733; (c) Araki, H.; Inoue, M.; Katoh, T. *Org. Lett.* **2003**, *5*, 3903; (d) Araki, H.; Inoue, M.; Suzuki, T.; Yamori, T.; Kohno, M.; Watanabe, K.; Abe, H.; Katoh, T. *Chem. Eur. J.* **2007**, *13*, 9866; (e) Clive, D. L. J.; Liu, D. *Angew. Chem. Int. Ed.* **2007**, *46*, 3738.
5. (a) Ryu, D. H.; Zhou, G.; Corey, E. J. *J. Org. Lett.* **2005**, *7*, 1633; (b) Ryu, D. H.; Zhou, G.; Corey, E. J. *J. Am. Chem. Soc.* **2004**, *126*, 4800; (c) Ryu, D. H.; Corey, E. J. *J. Am. Chem. Soc.* **2003**, *125*, 6388; (d) Ryu, D. H.; Lee, T. W.; Corey, E. J. *J. Am. Chem. Soc.* **2002**, *124*, 9992.
6. Ryu, D. H.; Kim, K. H.; Sim, J. Y.; Corey, E. J. *Tetrahedron Lett.* **2007**, *48*, 5735.
7. Compound **4** was prepared from 2-iodophenol in two steps in 60% yield by following the reported procedures: (a) Camps, P.; González, A.; Muñoz-Torrero, D.; Simon, M.; Zúñiga, A.; Martins, M. A.; Font-Bardia, M.; Solans, X. *Tetrahedron* **2000**, *56*, 8141; (b) Pirrung, M. C.; Nunn, D. S. *Tetrahedron Lett.* **1992**, *33*, 6591.
8. Breuning, M.; Corey, E. J. *Org. Lett.* **2001**, *3*, 1559.
9. Nicolaou, K. C.; Sasmal, P. K.; Xu, H. *J. Am. Chem. Soc.* **2004**, *126*, 5493.
10. Yun, J.; Kim, D.; Yun, H. *Chem. Commun.* **2005**, 5181.